Partial
Needs Revision
Patient Risk:
Moderate
Summary
Several interaction and liver/muscle-symptom counseling elements are consistent with the provided FDA label excerpts (notably grapefruit juice and liver function testing/caution). However, multiple claims add unsupported specificity or scope (e.g., grapefruit fruit/flavored/mixed juices and Seville orange/other juices; causal framing that is stronger than the label excerpts). Several symptom/indicator claims are not supported by the provided label text.
Category Scores
Accurate Statements
Grapefruit and grapefruit products can raise atorvastatin levels in the blood.
Supported by 7.2 (grapefruit juice components inhibit CYP3A4 and can increase plasma concentrations).
Grapefruit juice should be avoided or limited with atorvastatin.
Supported by 7.2 (excessive grapefruit juice consumption >1.2 liters/day) and 17.1 (risk increased with larger quantities >1 liter).
Heavy alcohol use can increase liver-stress risk.
Supported by 5.2 (use with caution in patients who consume substantial quantities of alcohol).
Atorvastatin can affect the liver in some people.
Supported by 5.2 (associated with biochemical abnormalities of liver function; liver enzyme abnormalities).
Unsupported Statements
Grapefruit fruit should be avoided or limited with atorvastatin.
Provided label excerpts specifically address grapefruit juice (7.2, 17.1) and do not support grapefruit fruit avoidance.
Products flavored with grapefruit, including some “natural” juices and mixed fruit juices, should be avoided or limited with atorvastatin.
No label support in provided excerpts for grapefruit-flavored/mixed or 'natural' juices beyond grapefruit juice.
Seville oranges and related orange products (sometimes used for marmalade) should be avoided or limited with atorvastatin.
No Seville orange interaction language appears in provided label excerpts.
Orange juice is not generally flagged the way grapefruit is with atorvastatin.
No provided label excerpt addresses orange juice comparisons.
Apple juice is not generally flagged the way grapefruit is with atorvastatin.
No provided label excerpt addresses apple juice.
Cranberry juice is not generally flagged the way grapefruit is with atorvastatin.
No provided label excerpt addresses cranberry juice.
The key interaction with fruit juices is specific to grapefruit (and Seville orange), not most fruit juices in general.
Provided label excerpts do not discuss Seville orange or general comparisons across most fruit juices.
Orange juice, apple juice, and cranberry juice generally do not have the same grapefruit-associated interaction risk as grapefruit and Seville orange.
No provided label excerpt evaluates interaction risk for orange/apple/cranberry juices.
High-dose red yeast rice contains a statin-like ingredient that can interact with atorvastatin.
No provided label excerpt mentions red yeast rice.
Some supplements advertised for cholesterol lowering without clear dosing/ingredient transparency can interact with atorvastatin.
No supplement-specific statements are present in the provided label excerpts.
Atorvastatin can be taken with or without food.
No meal/food timing statement appears in the provided label excerpts.
The main food to avoid with atorvastatin is grapefruit (and Seville orange), not whether it is taken with meals.
Label excerpt provided supports grapefruit juice interaction only; it does not support Seville orange or the 'main food' framing and meal-related comparison.
Dark or tea-colored urine suggests an interaction or too-high atorvastatin level.
No urine-color counseling is present in the provided label excerpts.
Severe nausea or vomiting suggests liver issues associated with atorvastatin.
No nausea/vomiting-to-liver guidance is present in the provided label excerpts.
Contradictions
Important Omissions
Recommended liver function test timing/monitoring details (prior to therapy and at 12 weeks after initiation and after dose increases, then periodically) were not included in the AI claims.
Importance:
Moderate
Label-based guidance that therapy should be temporarily withheld or discontinued in patients with an acute, serious condition suggestive of myopathy (risk factor for renal failure secondary to rhabdomyolysis) was not included in the AI claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported/overreaching food-interaction claims (e.g., grapefruit fruit/flavored/mixed juices; Seville orange; comparisons with other juices) could mislead patients to unnecessarily restrict or inaccurately assess risk. Some symptom-indicator claims (tea-colored urine; severe nausea/vomiting) are not supported by the provided label excerpts, which could distract from label-supported muscle symptom reporting and liver testing guidance.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Needs Revision
Primary Issue
Multiple claims extend beyond the provided label excerpts (scope expansion to grapefruit fruit/flavored/mixed juices and Seville orange; comparisons asserting other juices are not risky) and include unsupported symptom indicators and stronger causal phrasing than the label excerpts state.
Suggested Improvement
Limit interaction claims to what the provided label excerpts support (grapefruit juice and thresholds; reported myopathy/rhabdomyolysis and muscle pain/tenderness/weakness). Remove or qualify unsupported items (grapefruit fruit/flavored/mixed juices, Seville orange, orange/apple/cranberry comparisons, tea-colored urine, nausea/vomiting). Align symptom counseling and causality wording to label language (report unexplained muscle pain/tenderness/weakness; liver issues via jaundice example and emphasize recommended liver function testing).